Bio-Rad Laboratories (BIO) Net Equity Issued and Repurchased (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Net Equity Issued and Repurchased for 18 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 20.93% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $15.3 million (down 21.94% YoY), while the FY2019 annual figure was $13.1 million, down 7.22% from the prior year.
• Net Equity Issued and Repurchased steadied at $3.4 million in Q1 2026 per BIO's latest filing, from $3.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $7.6 million in Q3 2022 and bottomed at $3.4 million in Q3 2025.
• Historically, Net Equity Issued and Repurchased has averaged $4.7 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased jumped 148.84% — and 2025, when it plunged 33.33%.
• Bio-Rad Laboratories' Net Equity Issued and Repurchased stood at $7.6 million in 2022, then tumbled by 32.3% to $5.1 million in 2023, then declined by 0.22% to $5.1 million in 2024, then plunged by 33.33% to $3.4 million in 2025, then changed by 0.0% to $3.4 million in 2026.
• Business Quant data shows BIO's Net Equity Issued and Repurchased at $3.4 million in Q1 2026, $3.4 million in Q3 2025, and $4.2 million in Q2 2025.